Search Results
May 11, 2026, 04:30 ET Trial Results Support At-Home Treatment of Edema in Heart Failure with Subcutaneous Furosemide as an Effective and Safe Alternative to Inpatient Hospital Care
The pharmaceutical component of Lasix ONYU is a novel, high-concentration formulation of the diuretic furosemide, at 30 mg/mL. It comes in a pre-filled glass cartridge containing 80 mg of furosemide in 2.67 mL. The Lasix ONYU Infusor consists of two main parts: the Reusable Unit and the Disposable Unit.
More news about: SQ Innovation
May 11, 2026, 04:03 ET India struggles with a quit success rate under 5%: Experts back OTC access to NRT across all formats and dosages, including 2 mg and 4 mg
Making 2 mg and 4 mg NRTs widely available through OTC channels supports public health goals while maintaining regulatory oversight."Respire-2026 RecommendationsTo support national tobacco control objectives, experts recommended:Retain 2 mg and 4 mg NRTs as
More news about: The Asian Coalition for Health Empowerment (ACHE)
May 08, 2026, 14:58 ET Novo Nordisk lança nova condição especial (combo) para Wegovy® 2,4 mg: na compra de duas canetas, a terceira sai sem custo para o paciente
realizou a aprovação da nova dosagem de Wegovy® 7,2 mg no Brasil, que demonstrou perda de peso de 25% em 1 a cada 3 pacientes e perda de peso média de 21% segundo o estudo STEP UP.¹ A nova dosagem aprovada de 7,2 mg deve ser aplicada com três injeções de 2,4 mg no mesmo dia, uma vez por semana, conforme orientação
More news about: Novo Nordisk
May 08, 2026, 06:35 ET Knight Therapeutics anuncia a aprovação regulatória do TAVALISSE® no Brasil
inibidor da tirosina quinase do baço (SYK) administrado por via oral. Atualmente, está disponível nos Estados Unidos como TAVALISSE (comprimidos de 100 mg e 150 mg) e na Europa sob a marca TAVLESSE, para o tratamento de pacientes adultos com trombocitopenia imune crônica (PTI) que apresentaram resposta insuficiente
More news about: Knight Therapeutics Inc.
May 08, 2026, 06:35 ET Knight Therapeutics anuncia la aprobación regulatoria de TAVALISSE® en Brasil
tirosina quinasa del bazo (SYK) administrado por vía oral. Actualmente se encuentra disponible en Estados Unidos como TAVALISSE (tabletas de 100 mg y 150 mg) y en Europa bajo la marca TAVLESSE, para el tratamiento de pacientes adultos con trombocitopenia inmune (PTI) crónica que han presentado una respuesta
More news about: Knight Therapeutics Inc.
May 08, 2026, 05:21 ET AIKO sichert sich die französische 5,5%-Mehrwertsteuerberechtigung unter dem strengen PPE2 V2 Carbon Standard
CO₂-Äquivalent pro kWc, berechnet nach der PPE2 V2-Methode - die am schwierigsten zu erreichende AnforderungMaterielle Grenzen: Silber < 14 mg/W, Blei < 0,1 %, Cadmium < 0,01 %Vollständige Rückverfolgbarkeit: Produktionsstandort, Siliziumherkunft und Herstellungskette dokumentiert
More news about: AIKO
May 08, 2026, 02:30 ET Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
moderate in severity)LEQEMBI (lecanemab-irmb) is available:Intravenous infusion: 100 mg/mLSubcutaneous injection: 200 mg/mLPlease see full
More news about: Eisai Co., Ltd.
May 07, 2026, 18:48 ET AIKO obtient l'éligibilité à la TVA française à 5,5 % dans le cadre de la norme carbone PPE2 V2
CO₂ par kWc, calculé selon la méthodologie PPE2 V2 - l'exigence la plus difficile à atteindre.Limites des matériaux : argent < 14 mg/W, plomb < 0,1 %, cadmium < 0,01 %.Traçabilité complète : le site de production, l'origine du silicium et la chaîne de fabrication
More news about: AIKO
May 07, 2026, 16:05 ET Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
ELVN-001, reinforcing ELVN-001's positioning as the potentially best-in-class ATP-competitive inhibitor in CMLEnrollment continued in the 80 mg once daily expansion cohort of the Phase 1b trial evaluating ELVN-001 in patients with previously treated CML (
More news about: Enliven Therapeutics, Inc.
May 07, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Dose-dependent benefit on cUHDRS in Stage 2 participants relative to natural history cohort, with 52% slowing of disease progression at 10 mg doseContinued favorable safety and tolerability with no treatment-related NfL spikesPTC and Novartis will complete data review and
More news about: PTC Therapeutics, Inc.
May 07, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
progressing well in the Phase 3 PEAK and PINNACLE studies of KSI-101 in patients with macular edema secondary to inflammation (MESI), evaluating the 5 mg and 10 mg dose levels.Topline results from PEAK are expected in 4Q 2026.Topline results from PINNACLE are expected in 2Q 2027.On
More news about: Kodiak Sciences Inc.
May 07, 2026, 10:01 ET AIKO obtiene la elegibilidad para el IVA francés del 5,5% bajo la estricta norma de carbono PPE2 V2
equivalente por kWc, calculado según la metodología PPE2 V2; este es el requisito más difícil de cumplir.Límites de materiales: Plata < 14 mg/W, plomo < 0,1%, cadmio < 0,01%.Trazabilidad completa: El lugar de producción, el origen del silicio y la cadena de fabricación están
More news about: AIKO
May 07, 2026, 10:00 ET Ultra Launches Sleep Pouches: A Six-Ingredient, Clinically-Backed Sleep Stack You Can Feel in as Little as 5-10 Minutes
contains:1 mg Melatonin — Signals the brain that it's time to sleep and supports circadian rhythm regulation.50 mg L-Theanine — Promotes calm alpha brain waves and reduces racing thoughts without sedation.30 mg Magnesium Gluconate — Supports
More news about: Ultra
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
18.57%, to close at $5.50 per share on March 5, 2026. Then, on March 30, 2026, PepGen issued a press release announcing "clinical data from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1)." Although PepGen
More news about: Pomerantz LLP
May 07, 2026, 09:01 ET 再鼎醫藥公布 2026年第一季度財務業績和近期公司進展
伴腦轉移的SCLC：Zoci顯示經確認的顱內客觀緩解率（iORR）為53.7%，其中在1.6 mg/kg劑量下達到62.5%（10/16），包括完全緩解。值得注意的是，在既往未接受過腦部放療的患者中也觀察到了緩解（9/15，60%），凸顯了這款藥物對顱內病灶的淨效應。Zoci耐受性良好，總人群≥3級的治療相關不良事件 （TRAEs）發生率為19.9%（27/136），而接受1.6mg/kg劑量的患者為16.4%（9/55）。epNECs：觀察到令人鼓舞的抗腫瘤活性，在不同原發部位的epNEC腫瘤中，經確認的客觀緩解率為38.2%。epNEC中的安全性特征與既往在SCLC中觀察到的一致，1b期患者中≥3級TRAEs發生率為15.2%。
More news about: 再鼎醫藥
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
May 07, 2026, 07:00 ET Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026
medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.Centers for Disease Control and Prevention.
More news about: Novo Nordisk
May 07, 2026, 06:59 ET Viatris Reports First-Quarter 2026 Financial Results
Company announced that Japan's Ministry of Health, Labour and Welfare approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor, for the treatment of adults with generalized anxiety disorder.2026
More news about: Viatris Inc.
May 07, 2026, 04:23 ET AIKO Secures French 5.5% VAT Eligibility Under Stringent PPE2 V2 Carbon Standard
equivalent per kWc, calculated under PPE2 V2 methodology – the most difficult requirement to achieveMaterial limits: Silver < 14 mg/W, lead < 0.1%, cadmium < 0.01%Full traceability: Production site, silicon origin, and manufacturing chain documented and auditable,
More news about: AIKO
May 06, 2026, 18:15 ET Frasle Mobility reports net revenue of R$ 1.2 billion in the first quarter of 2026
several factors. On the domestic front, the quarter included operational adjustments, such as the completion of the ERP system upgrade at the Extrema (MG) plant, as well as the start of operations of the new 4Mobility logistics automation system. The external environment also pressured the Company's profitability,
More news about: Frasle Mobility
May 06, 2026, 18:10 ET Frasle Mobility alcanza ingresos netos de R$ 1,2 mil millones en el primer trimestre de 2026
factores. En el ámbito interno, el trimestre concentró ajustes operativos, como la finalización de la actualización del sistema ERP en la unidad de Extrema (MG), además del inicio de operaciones del nuevo sistema de automatización logística 4Mobility. El entorno externo también presionó la rentabilidad de la
More news about: Frasle Mobility
May 06, 2026, 16:54 ET Novo Nordisk lança no Brasil terapia semanal para crianças e adultos com deficiência do hormônio do crescimento
mais de 2 mil funcionários. Está presente em dois estados, com um escritório administrativo em São Paulo (SP) e um site produtivo em Montes Claros (MG). Para mais informações, visite www.novonordisk.com.br e siga nossos perfis
More news about: Novo Nordisk
May 06, 2026, 12:10 ET 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
advantage is even more pronounced. The proportion of participants achieving ≥5% weight loss from baseline reached 84.7%, 89.8%, and 94.6% in the 5 mg, 10 mg, and 15 mg dose groups, respectively.
More news about: BrightGene
May 06, 2026, 11:16 ET STORM Launches Nationwide, Redefining Energy for a New Generation
STORM, where performance meets lifestyle, and communities are formed through shared values and aspirations.Each 12 oz. can of STORM delivers 200mg of caffeine to enhance focus and sustain energy when you need it, combined with a zero-sugar formula for a delicious yet guilt-free experience. Designed
More news about: STORM
May 06, 2026, 10:23 ET FullWell Launches Strawberry-Flavor Capsule-Free Prenatal Stick Packs
(275 mg), vitamin D (100 mcg (4000 IU)), vitamin E (100 mg), thiamin (5 mg), riboflavin (10 mg), niacin (25 mg NE), vitamin B6 (10 mg), folate (1360 mcf DFE), vitamin B12 (150 mcg), biotin (500 mcg), pantothenic acid (150 mg), choline (300 mg), calcium (400 mg), iodine (250 mg), magnesium (300 mg), zinc20
More news about: FullWell